Recombinant SARS-CoV-2 Spike (Sotrovimab Biosimilar) anticorps

N° du produit ABIN7795140

L’anticorps anti-SARS-CoV-2 Spike (Sotrovimab Biosimilar) Monoclonal produit chez le Human a été validé pour FACS et in vivo. Il convient pour la détection de SARS-CoV-2 Spike (Sotrovimab Biosimilar) dans des échantillons provenant de Humain. }

Aperçu rapide pour Recombinant SARS-CoV-2 Spike (Sotrovimab Biosimilar) anticorps (ABIN7795140)

Antigène: SARS-CoV-2 Spike (Sotrovimab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Human

Clonalité: Monoclonal

Conjugué: Cet anticorp SARS-CoV-2 Spike (Sotrovimab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Détail du produit anti-SARS-CoV-2 Spike (Sotrovimab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Afucosylated Sotrovimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody

Attributs du produit: What is sotrovimab biosimilar research grade? Sotrovimab is an Fc-engineered human monoclonal antibody directed against the spike protein of SARS-CoV-2. sotrovimab is a human monoclonal antibody (IgG1κ isotype). sotrovimab biosimilar uses the same protein sequences as the therapeutic antibody sotrovimab. sotrovimab/imdevimab is a combination medicine used for the treatment and prevention of COVID-19. It consists of two human monoclonal antibodies, sotrovimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. sotrovimab and imdevimab bind distinct epitopes on the RBD with dissociation constants KD of 46 and 47 pM, respectively. Please contact us if you are interested in the anti-SARS-CoV-2 spike monoclonal antibody imdevimab biosimilar.

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method

Isotype: IgG1, kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Stock: 4 °C,-20 °C

Stockage commentaire: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Détails sur SARS-CoV-2 Spike (Sotrovimab Biosimilar)

Antigène: SARS-CoV-2 Spike (Sotrovimab Biosimilar)

Autre désignation: Sotrovimab Biosimilar

Classe de substances: Biosimilar